n-benzyladriamycin-14-valerate has been researched along with imatinib mesylate in 1 studies
| Studies (n-benzyladriamycin-14-valerate) | Trials (n-benzyladriamycin-14-valerate) | Recent Studies (post-2010) (n-benzyladriamycin-14-valerate) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 25 | 0 | 3 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | n-benzyladriamycin-14-valerate (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lothstein, L; Savranskaya, L; Sweatman, TW | 1 |
1 other study(ies) available for n-benzyladriamycin-14-valerate and imatinib mesylate
| Article | Year |
|---|---|
N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Topics: Antibiotics, Antineoplastic; Apoptosis; Benzamides; Cytochromes c; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; Immunoblotting; K562 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Piperazines; Protein Kinase C; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; STAT5 Transcription Factor | 2007 |